Systemic and intracerebroventricular effects of opioid peptides in withdrawn morphine-dependent rhesus monkeys

Debra E. Gmerek, Jonathan L. Katz, Charles P. France, James H. Woods

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

The effects of the degradation-resistant enkephalin analogs FK 33-824 and metkephamid were determined after systemic and intracerebroventricular (i.c.v.) administration in withdrawn morphine-dependent rhesus monkeys. Both peptides suppressed completely signs of 12-hr morphine deprivation, as does the prototype mu-receptor agonist morphine. The peptides were 100 and 2000 times more potent, respectively, after i.c.v. than s.c. injection. Thus, although peptidase-resistant, these compounds have restricted entrance into the central nervous system after systemic administration. The i.c.v. administration of compounds in rhesus monkeys should prove to be a valuable tool in the study of peptide ligands for opiate receptors.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalLife Sciences
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - 1983

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Systemic and intracerebroventricular effects of opioid peptides in withdrawn morphine-dependent rhesus monkeys'. Together they form a unique fingerprint.

Cite this